VIA to continue heart drug trials after safety profile review
April 4th, 2008 | by admin |April 4 (Reuters) - VIA Pharmaceuticals Inc (VIAP.O: Quote, Profile, Research) saidit will continue with the mid-stage trials of its heart drug,VIA-2991, after an independent panel observed a continuedacceptable safety profile of the drug.
The company said the independent data safety monitoringboard recommended VIA continue the ongoing trials as planned.VIA expects to release its first proof-of-concept data laterthis year. (Reporting by Jennifer Robin Raj in Bangalore; Editing byHimani Sarkar)
